Tags

Type your tag names separated by a space and hit enter

Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care.
Cancers (Basel). 2020 Jun 27; 12(7)C

Abstract

Patients living with brain tumours have the highest average years of life lost of any cancer, ultimately reducing average life expectancy by 20 years. Diagnosis depends on brain imaging and most often confirmatory tissue biopsy for histology. The majority of patients experience non-specific symptoms, such as headache, and may be reviewed in primary care on multiple occasions before diagnosis is made. Sixty-two per cent of patients are diagnosed on brain imaging performed when they deteriorate and present to the emergency department. Histological diagnosis from invasive surgical biopsy is necessary prior to definitive treatment, because imaging techniques alone have difficulty in distinguishing between several types of brain cancer. However, surgery itself does not necessarily control tumour growth, and risks morbidity for the patient. Due to their similar features on brain scans, glioblastoma, primary central nervous system lymphoma and brain metastases have been known to cause radiological confusion. Non-invasive tests that support stratification of tumour subtype would enhance early personalisation of treatment selection and reduce the delay and risks associated with surgery for many patients. Techniques involving vibrational spectroscopy, such as attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, have previously demonstrated analytical capabilities for cancer diagnostics. In this study, infrared spectra from 641 blood serum samples obtained from brain cancer and control patients have been collected. Firstly, we highlight the capability of ATR-FTIR to distinguish between healthy controls and brain cancer at sensitivities and specificities above 90%, before defining subtle differences in protein secondary structures between patient groups through Amide I deconvolution. We successfully differentiate several types of brain lesions (glioblastoma, meningioma, primary central nervous system lymphoma and metastasis) with balanced accuracies >80%. A reliable blood serum test capable of stratifying brain tumours in secondary care could potentially avoid surgery and speed up the time to definitive therapy, which would be of great value for both neurologists and patients.

Authors+Show Affiliations

WestCHEM, Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George St, Glasgow G1 1RD, UK.WestCHEM, Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George St, Glasgow G1 1RD, UK.ClinSpec Diagnostics, University of Strathclyde, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK.ClinSpec Diagnostics, University of Strathclyde, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK.Translational Neurosurgery, Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, UK.Institute of Translational Medicine, University of Liverpool & The Walton Centre NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK.Walton Research Tissue Bank, Neurosciences Labs, The Walton Centre NHS Foundation Trust, Lower lane, Fazakerley, Liverpool L9 7LJ UK.Neuropathology, Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Sharoe Green Lane North, Preston, Lancashire PR2 9HT, UK.Neuropathology, Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Sharoe Green Lane North, Preston, Lancashire PR2 9HT, UK.ClinSpec Diagnostics, University of Strathclyde, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK. WestCHEM, Department of Pure and Applied Chemistry, Thomas Graham Building, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK.WestCHEM, Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George St, Glasgow G1 1RD, UK. ClinSpec Diagnostics, University of Strathclyde, Technology and Innovation Centre, 99 George Street, Glasgow G1 1RD, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32605100

Citation

Cameron, James M., et al. "Stratifying Brain Tumour Histological Sub-Types: the Application of ATR-FTIR Serum Spectroscopy in Secondary Care." Cancers, vol. 12, no. 7, 2020.
Cameron JM, Rinaldi C, Butler HJ, et al. Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care. Cancers (Basel). 2020;12(7).
Cameron, J. M., Rinaldi, C., Butler, H. J., Hegarty, M. G., Brennan, P. M., Jenkinson, M. D., Syed, K., Ashton, K. M., Dawson, T. P., Palmer, D. S., & Baker, M. J. (2020). Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care. Cancers, 12(7). https://doi.org/10.3390/cancers12071710
Cameron JM, et al. Stratifying Brain Tumour Histological Sub-Types: the Application of ATR-FTIR Serum Spectroscopy in Secondary Care. Cancers (Basel). 2020 Jun 27;12(7) PubMed PMID: 32605100.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care. AU - Cameron,James M, AU - Rinaldi,Christopher, AU - Butler,Holly J, AU - Hegarty,Mark G, AU - Brennan,Paul M, AU - Jenkinson,Michael D, AU - Syed,Khaja, AU - Ashton,Katherine M, AU - Dawson,Timothy P, AU - Palmer,David S, AU - Baker,Matthew J, Y1 - 2020/06/27/ PY - 2020/06/02/received PY - 2020/06/19/revised PY - 2020/06/25/accepted PY - 2020/7/2/entrez PY - 2020/7/2/pubmed PY - 2020/7/2/medline KW - Brain Cancer KW - Diagnostics KW - Infrared KW - Serum KW - Spectroscopy KW - Tumour Stratification JF - Cancers JO - Cancers (Basel) VL - 12 IS - 7 N2 - Patients living with brain tumours have the highest average years of life lost of any cancer, ultimately reducing average life expectancy by 20 years. Diagnosis depends on brain imaging and most often confirmatory tissue biopsy for histology. The majority of patients experience non-specific symptoms, such as headache, and may be reviewed in primary care on multiple occasions before diagnosis is made. Sixty-two per cent of patients are diagnosed on brain imaging performed when they deteriorate and present to the emergency department. Histological diagnosis from invasive surgical biopsy is necessary prior to definitive treatment, because imaging techniques alone have difficulty in distinguishing between several types of brain cancer. However, surgery itself does not necessarily control tumour growth, and risks morbidity for the patient. Due to their similar features on brain scans, glioblastoma, primary central nervous system lymphoma and brain metastases have been known to cause radiological confusion. Non-invasive tests that support stratification of tumour subtype would enhance early personalisation of treatment selection and reduce the delay and risks associated with surgery for many patients. Techniques involving vibrational spectroscopy, such as attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, have previously demonstrated analytical capabilities for cancer diagnostics. In this study, infrared spectra from 641 blood serum samples obtained from brain cancer and control patients have been collected. Firstly, we highlight the capability of ATR-FTIR to distinguish between healthy controls and brain cancer at sensitivities and specificities above 90%, before defining subtle differences in protein secondary structures between patient groups through Amide I deconvolution. We successfully differentiate several types of brain lesions (glioblastoma, meningioma, primary central nervous system lymphoma and metastasis) with balanced accuracies >80%. A reliable blood serum test capable of stratifying brain tumours in secondary care could potentially avoid surgery and speed up the time to definitive therapy, which would be of great value for both neurologists and patients. SN - 2072-6694 UR - https://www.unboundmedicine.com/medline/citation/32605100/Stratifying_Brain_Tumour_Histological_Sub-Types:_The_Application_of_ATR-FTIR_Serum_Spectroscopy_in_Secondary_Care L2 - https://www.mdpi.com/resolver?pii=cancers12071710 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.